Manhattan Scientifics Inc (MHTX)

[rustydog62]

IBX, some great news from an independent blinded review by a panel of expert breast cancer radiologists which has corroborated previously reported positive findings for the company’s MagSense diagnostic tech.

The company says that the radiologists confirmed that the “MagSense HER2 imaging agent produces a change in image contrast and that the contrast in nodes highly suspicious for tumour is distinctly different from the MR image contrast seen in non-involved nodes”.

“The outcome of the independent review is welcome news, indeed,” Imagion Biosystems CEO Bob Proulx said.

“We now have a clear indication that our MagSense magnetic nanoparticle technology could work with the existing medical imaging infrastructure to provide the clinical benefit to breast cancer patients we have been aiming for.

“This takes a lot of the technical risk out of the future and will significantly facilitate market entry by eliminating the need to design, make, sell, and support new machinery.”